Loading...
Elixinol Wellness Limited
EXL.AX•ASX
Healthcare
Drug Manufacturers - Specialty & Generic
A$0.02
A$0.00(0.00%)

Over the last four quarters, Elixinol Wellness Limited's revenue moved from $3.84M in Q4 2022 to $6.77M in Q2 2024. Operating income in Q2 2024 was -$1.97M, with a strong operating margin of -29%. Despite fluctuations in R&D and SG&A expenses, EBITDA for Elixinol Wellness Limited remained robust at -$2.37M, reflecting operational efficiency. Net income rose to -$2.76M, with an EPS of -$0.003. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan